Lately, the efficacy of ALK inhibitors had shown potential in ALK-driven refractory or relapsed neuroblastoma [12] and is currently being investigated as upfront treatment for newly diagnosed patients with high-risk disease and confirmed ALK mutated tumors (COG ANBL1531, ClinicalTrails.gov identifier NCT03126916). The gene discussed is ALK; the disease is neuroblastoma.